Subscribe today to HTA Quarterly - the e-newsletter with insights to bridge science and policy.

As a strategic consulting partner for hundreds of brands, we’ve learned what insights HEOR and Market Access teams find most useful. And we’ve designed an e-newsletter specifically with your needs in mind.

Take a look at what's in our current issue: 

  • Feature Story:
    Recent Trends in Oncology Appraisal Decisions: A Comparison between the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC)
  • Therapeutic Spotlight:
    The Struggle to Achieve Market Access Across the Globe for Cell and Gene Therapies
  • Market Trends and Updates:
    Is there Consensus on Implementing Coverage with Evidence Development?

From at-a-glance updates on important HTA decisions, to reviews that shine a spotlight on what those decisions mean for specific therapeutic areas, each edition of the HTA Quarterly provides insight into the evolving perspectives and priorities for HTAs; as well as Xcenda’s unique perspective so you are more prepared to address the challenges of an uncertain and rapidly changing healthcare environment.